• home
• research
• publications
• people

Publications 2008-Present

• Johnson N, Speirs V, Curtin NJ and Hall AG. A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer. Breast Cancer Res Treat. 2008 Sep;111(1):55-63.
• Johnson N, Cai D, Kennedy RD, Pathania S, Arora M, Li YC, D’Andrea AD, Parvin J.D and Shapiro GI. Cdk1 participates in BRCA1-dependent S phase checkpont control in response to DNA damage.  Molecular Cell. 2009 Aug 14;35(3):327-39.
• Johnson N, Bentley J, Wang LZ, Newell DR, Robson CN, Shapiro GI, Curtin NJ. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen sensitive and resistant breast cancer cells. Br J Cancer. 2010 Jan 19;102(2):342-50.
• Johnson N and Shapiro GI. Targeting cyclin-dependent kinases for cancer therapy.  Cell cycle deregulation in cancer; GH Enders (ed.) 2010.
•  Johnson N, Shapiro GI Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets.  2010 Nov; 14(11):1199-212.
• Johnson N, Li Y-C, Walton ZE, Cheng KA, Li D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D’Andrea AD, Curtin NJ, Wong KK, Shapiro GI.  Compromised cdk1 activity sensitizes BRCA-proficient cancers to PARP inhibition.  Nature Medicine. 2011 Jun 26;17(7):875-82.
• Johnson N, Shapiro GI. Chemotherapy-induced p53-dependent and -independent DNA damage responses are enhanced by poly(ADP-ribose) polymerase (PARP) inhibition in BRCA-proficient cancer cells. Cell Cycle. 2012 Feb 1;11(3):432-3.
• Johnson N, Shapiro GI. Cyclin-dependent kinase 4/6 inhibition in cancer therapy. Cell Cycle. 2012 Nov 1;11(21):3913.
• Johnson N, Johnson SF, Yao W, Li Y-L, Choi Y-E, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell M, Liu JF, D’Andrea AD, Miron A, Swisher EM, Shapiro GI. Stabilization of mutant BRCA1 confers PARP inhibitor and platinum resistance.  Manuscript under review.
• Johnson N, Johnson SF, Chi D, Primack B, D’Andrea AD, Lim E, Shapiro GI. The CDK inhibitor dinaciclib sensitizes triple-negative breast cancer cells to PARP inhibition. Manuscript in preparation.